Disorders of hemostasis in acute leukemia

II

H. Al Mondhiry

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Bleeding is a frequent complication in patients with acute leukemia. The most common cause of hemorrhage is thrombocytopenia. The incidence of serious and, at times, life threatening bleeding is high when the platelet count is below 10,000 cu mm, particularly when fever and infection are present. Patients with acute granulocytic leukemia and a white cell count above 100,000 cu mm have a high risk of intracranial hemorrhage, even in the presence of a normal platelet count. Platelet transfusion is effective in the treatment and prophylaxis of bleeding in leukemic patients with thrombocytopenia. Patients with sepsis often respond poorly to platelet transfusion. Patients who have been repeatedly transfused may become allosensitized and unresponsive to random platelet therapy. In such circumstances, transfusion of platelets from HL-A matched donors is more effective. Disseminated intravascular coagulation may complicate the course of acute leukemia. Patients with acute promyelocytic leukemia and all patients with AL and sepsis and uncontrollable disease are at special risk for development of this complication. The main therapeutic effort should be to control the infection and induce remission, if possible. Treatment with heparin may be helpful to tide such patients over a crisis period until more definite therapy can be initiated. Supportive care is essential. Transfusions with platelets, fresh frozen plasma and packed red cells is often required. Occasionally, other hemostatic defects such as clotting factors deficiency due to liver disease, vitamin K deficiency, platelet dysfunction or circulating anticoagulant may be present and require appropriate therapeutic measures.

Original languageEnglish (US)
Pages (from-to)51-56
Number of pages6
JournalClinical Bulletin
Volume5
Issue number2
StatePublished - 1975

Fingerprint

Hemostasis
Leukemia
Platelet Transfusion
Hemorrhage
Platelet Count
Thrombocytopenia
Sepsis
Therapeutics
Blood Platelets
Vitamin K Deficiency
Acute Promyelocytic Leukemia
Myeloid Leukemia
Blood Coagulation Factors
Intracranial Hemorrhages
Disseminated Intravascular Coagulation
Hemostatics
Infection Control
Heparin
Liver Diseases
Fever

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Al Mondhiry, H. / Disorders of hemostasis in acute leukemia : II. In: Clinical Bulletin. 1975 ; Vol. 5, No. 2. pp. 51-56.
@article{15121f6e0ed54d6592a5960c66d2c6a4,
title = "Disorders of hemostasis in acute leukemia: II",
abstract = "Bleeding is a frequent complication in patients with acute leukemia. The most common cause of hemorrhage is thrombocytopenia. The incidence of serious and, at times, life threatening bleeding is high when the platelet count is below 10,000 cu mm, particularly when fever and infection are present. Patients with acute granulocytic leukemia and a white cell count above 100,000 cu mm have a high risk of intracranial hemorrhage, even in the presence of a normal platelet count. Platelet transfusion is effective in the treatment and prophylaxis of bleeding in leukemic patients with thrombocytopenia. Patients with sepsis often respond poorly to platelet transfusion. Patients who have been repeatedly transfused may become allosensitized and unresponsive to random platelet therapy. In such circumstances, transfusion of platelets from HL-A matched donors is more effective. Disseminated intravascular coagulation may complicate the course of acute leukemia. Patients with acute promyelocytic leukemia and all patients with AL and sepsis and uncontrollable disease are at special risk for development of this complication. The main therapeutic effort should be to control the infection and induce remission, if possible. Treatment with heparin may be helpful to tide such patients over a crisis period until more definite therapy can be initiated. Supportive care is essential. Transfusions with platelets, fresh frozen plasma and packed red cells is often required. Occasionally, other hemostatic defects such as clotting factors deficiency due to liver disease, vitamin K deficiency, platelet dysfunction or circulating anticoagulant may be present and require appropriate therapeutic measures.",
author = "{Al Mondhiry}, H.",
year = "1975",
language = "English (US)",
volume = "5",
pages = "51--56",
journal = "Clinical Bulletin",
number = "2",

}

Al Mondhiry, H 1975, 'Disorders of hemostasis in acute leukemia: II', Clinical Bulletin, vol. 5, no. 2, pp. 51-56.

Disorders of hemostasis in acute leukemia : II. / Al Mondhiry, H.

In: Clinical Bulletin, Vol. 5, No. 2, 1975, p. 51-56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Disorders of hemostasis in acute leukemia

T2 - II

AU - Al Mondhiry, H.

PY - 1975

Y1 - 1975

N2 - Bleeding is a frequent complication in patients with acute leukemia. The most common cause of hemorrhage is thrombocytopenia. The incidence of serious and, at times, life threatening bleeding is high when the platelet count is below 10,000 cu mm, particularly when fever and infection are present. Patients with acute granulocytic leukemia and a white cell count above 100,000 cu mm have a high risk of intracranial hemorrhage, even in the presence of a normal platelet count. Platelet transfusion is effective in the treatment and prophylaxis of bleeding in leukemic patients with thrombocytopenia. Patients with sepsis often respond poorly to platelet transfusion. Patients who have been repeatedly transfused may become allosensitized and unresponsive to random platelet therapy. In such circumstances, transfusion of platelets from HL-A matched donors is more effective. Disseminated intravascular coagulation may complicate the course of acute leukemia. Patients with acute promyelocytic leukemia and all patients with AL and sepsis and uncontrollable disease are at special risk for development of this complication. The main therapeutic effort should be to control the infection and induce remission, if possible. Treatment with heparin may be helpful to tide such patients over a crisis period until more definite therapy can be initiated. Supportive care is essential. Transfusions with platelets, fresh frozen plasma and packed red cells is often required. Occasionally, other hemostatic defects such as clotting factors deficiency due to liver disease, vitamin K deficiency, platelet dysfunction or circulating anticoagulant may be present and require appropriate therapeutic measures.

AB - Bleeding is a frequent complication in patients with acute leukemia. The most common cause of hemorrhage is thrombocytopenia. The incidence of serious and, at times, life threatening bleeding is high when the platelet count is below 10,000 cu mm, particularly when fever and infection are present. Patients with acute granulocytic leukemia and a white cell count above 100,000 cu mm have a high risk of intracranial hemorrhage, even in the presence of a normal platelet count. Platelet transfusion is effective in the treatment and prophylaxis of bleeding in leukemic patients with thrombocytopenia. Patients with sepsis often respond poorly to platelet transfusion. Patients who have been repeatedly transfused may become allosensitized and unresponsive to random platelet therapy. In such circumstances, transfusion of platelets from HL-A matched donors is more effective. Disseminated intravascular coagulation may complicate the course of acute leukemia. Patients with acute promyelocytic leukemia and all patients with AL and sepsis and uncontrollable disease are at special risk for development of this complication. The main therapeutic effort should be to control the infection and induce remission, if possible. Treatment with heparin may be helpful to tide such patients over a crisis period until more definite therapy can be initiated. Supportive care is essential. Transfusions with platelets, fresh frozen plasma and packed red cells is often required. Occasionally, other hemostatic defects such as clotting factors deficiency due to liver disease, vitamin K deficiency, platelet dysfunction or circulating anticoagulant may be present and require appropriate therapeutic measures.

UR - http://www.scopus.com/inward/record.url?scp=0016757526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0016757526&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 51

EP - 56

JO - Clinical Bulletin

JF - Clinical Bulletin

IS - 2

ER -